Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
80°
Partly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lexaria Bioscience Corp
(NQ:
LEXX
)
3.030
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lexaria Bioscience Corp
< Previous
1
2
3
4
5
6
7
8
9
...
28
29
Next >
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
March 14, 2024
Via
ACCESSWIRE
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
March 12, 2024
Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
March 12, 2024
Via
Benzinga
Why Lexaria Bioscience (LEXX) Shares Are Moving
February 15, 2024
Lexaria Bioscience shares are trading lower by 6.5% Thursday morning. The company finalized agreements for a registered direct offering.
Via
Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Banking on DehydraTECH(TM) Technology for Major 2024 Growth
March 08, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Banking on DehydraTECH(TM) Technology for Major 2024 Growth
March 08, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires CRO for Second DehydraTECH-Powered GLP-1 Human Pilot Study
March 07, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Awards Contract For Next GLP-1 Human Pilot Study
March 07, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Commence Diabetes and Weight Loss Animal Study
March 05, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Commence Diabetes and Weight Loss Animal Study
March 05, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
March 05, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Weight-Loss Results in Animal Study, Begins Eight-Week Follow-Up Study
March 04, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Weight-Loss Results in Animal Study, Begins Eight-Week Follow-Up Study
March 04, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Study
March 04, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Commence HYPER-H23-1 Clinical Trial
March 01, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Commence HYPER-H23-1 Clinical Trial
March 01, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial
March 01, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Wednesday's After-Market Session
February 28, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
February 27, 2024
Via
Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Closing of $3.6 Million Registered Direct Offering
February 27, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Closing of $3.6 Million Registered Direct Offering
February 27, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Closing of $3.6M Registered Direct Offering
February 20, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Closing of $3.6M Registered Direct Offering
February 20, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Doubles Down on GLP-1 Clinical Studies for 2024; Terms 2023 as its Most Successful and Active Year of R&D
February 20, 2024
Via
Investor Brand Network
Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
February 16, 2024
Via
ACCESSWIRE
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on $3.6M Registered Direct Offering
February 15, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
February 15, 2024
Via
ACCESSWIRE
Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks off 2024 with FDA IND Submission for its HYPER-H23-1 Phase 1b Human Clinical Trial
February 14, 2024
Via
Investor Brand Network
Exposures
Product Safety
TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Patented DehydraTECH(TM) Improves Delivery of GLP-1 Drug to Bloodstream
February 12, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) CEO, Chris Bunka, Shares 2023 Company Update and 2024 Roadmap in Annual Letter
February 12, 2024
Via
Investor Brand Network
< Previous
1
2
3
4
5
6
7
8
9
...
28
29
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.